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Introduction
There are many complications of severe acute pancreatitis
(SAP), but infected pancreatic necrosis and pancreatic
abscess are very serious and relate to the mortality and
morbidity. Recently there have been many studies about
the utility of procalcitonin (PCT) as a factor of prediction
for infective complications in SAP.
Objectives
To clarify the utility of PCT as a factor of prediction for
infected pancreatic necrosis and pancreatic abscess.
Methods
In a single center of the Advanced Emergency Medical
Center in Japan, the 25 patients diagnosed as SAP in
accordance with the criteria of Japanese Ministry of
Health, Labour and Welfare. We measured their PCT
once a day during the first week after hospitalization and
three times a week after first week during they were in the
hospital. The fine needle aspiration (FNA) was adminis-
tered, when we suspect the existence of infective compli-
cation during the course of SAP. The definition of
existence of infective complication is to be bacteriologi-
cally-positive. Comparative review was conducted on the
PCT level of both groups. Review 1 is to compare the
maximum PCT level of with and without infected compli-
cation, both were recorded within 1 week after hospitaliza-
tion. Review 2 is to compare the maximum PCT level of
with infected complication recorded during 1 week before
proved infection and that of without recorded within 1
week after hospitalization.
Results
The 19 of the 25 patients of SAP ware included because
6 patients of them had been excluded due to passing
away within 1 week. Of the remaining 19 patients, 9
represented infective complication (infected group) and
10 were none (non-infected group). All the infected com-
plication developed at least 1 week after their hospitaliza-
tion. The infected group’s median age, APACHE II score,
and SOFA score were, respectively, 73 years old (inter-
quartile range (IQR) 55 to 80), 18(IQR 13 to 22), and
7(IQR 3 to 10), those of the non-infected group were
49 years old (IQR 43 to 73), 12(IQR 9 to 20), and 4(IQR 3
to 8), which show no significant differences. Review 1: The
infected group’s maximum PCT level was higher, but have
largely varied and shown no significant difference
(2.3µg/dl vs.0.8µg/dl : p = 0.09). Review 2: The maximum
PCT level of the infected group was found to have
increased with statistical significance as compared to that
of the non-infected group (0.7µg/dl vs. 0.2µg/dl : p = 0.05).
Assuming the PCT cut off value being 0.5µg/dl, the
sensitivity and specificity of PCT during the infective
complication were 0.55 and 0.9, respectively.
Conclusions
While the elevated PCT during course management of
SAP will possibly give an indication of the infective com-
plication, its clinical application requires further collection
of the clinical data as it is no more than just slightly higher
than the upper limit of normal level according our results
of this study.
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